company background image
ADTX

Aditxt NasdaqCM:ADTX Stock Report

Last Price

US$0.17

Market Cap

US$9.4m

7D

0.06%

1Y

-92.1%

Updated

11 Aug, 2022

Data

Company Financials
ADTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ADTX Stock Overview

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.

Aditxt, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aditxt
Historical stock prices
Current Share PriceUS$0.17
52 Week HighUS$3.95
52 Week LowUS$0.12
Beta1.39
1 Month Change-12.62%
3 Month Change-41.40%
1 Year Change-92.15%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.63%

Recent News & Updates

Jul 08

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Aditxt (NASDAQ:ADTX) said on Friday that it completed a toxicology study that indicated the safety of its immunotherapeutic technology drug ADI-100, to treat rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. (ADTX) stock surged 61% before the bell. The company said that the result will provide help when the company files an Investigational New Drug (IND) application with the regulatory agencies.

Shareholder Returns

ADTXUS BiotechsUS Market
7D0.06%1.2%1.3%
1Y-92.1%-23.0%-11.7%

Return vs Industry: ADTX underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: ADTX underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is ADTX's price volatile compared to industry and market?
ADTX volatility
ADTX Average Weekly Movement26.9%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ADTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 27% a week.

Volatility Over Time: ADTX's weekly volatility has increased from 21% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201758Amro Albannahttps://www.aditxt.com

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.

Aditxt, Inc. Fundamentals Summary

How do Aditxt's earnings and revenue compare to its market cap?
ADTX fundamental statistics
Market CapUS$9.43m
Earnings (TTM)-US$46.05m
Revenue (TTM)US$315.31k

29.9x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADTX income statement (TTM)
RevenueUS$315.31k
Cost of RevenueUS$266.05k
Gross ProfitUS$49.26k
Other ExpensesUS$46.10m
Earnings-US$46.05m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.83
Gross Margin15.62%
Net Profit Margin-14,604.80%
Debt/Equity Ratio13.3%

How did ADTX perform over the long term?

See historical performance and comparison